Retraction Note: metastatic collecting duct carcinoma of the kidney treated with Sunitinib

  • Tazi E
  • Essadi I
  • Tazi M
  • et al.
N/ACitations
Citations of this article
3Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Collecting duct carcinoma (CDC) of the kidney is a rare and aggressive malignant tumor arising from the distal collecting tubules which has been shown to have a poor response to several kinds of systemic therapy. We present a case of metastatic CDC that responded favorably to a multiple tyrosine kinase inhibitor, sunitinib, achieving a partial response in both lung and skeletal metastases. To our knowledge, this is the first report showing therapeutic activity of sunitinib against CDC. Considering these findings, it would be worthwhile prospectively investigating the role of multiple tyrosine kinase inhibitors, particularly sunitinib, in the management of metastatic CDC.

Cite

CITATION STYLE

APA

Tazi, E. M., Essadi, I., Tazi, M. F., Ahellal, Y., M’rabti, H., & Errihani, H. (2011). Retraction Note: metastatic collecting duct carcinoma of the kidney treated with Sunitinib. World Journal of Surgical Oncology, 9(1). https://doi.org/10.1186/1477-7819-9-136

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free